Search

Your search keyword '"Jakubowiak, Andrzej"' showing total 982 results
Start Over Author "Jakubowiak, Andrzej" Search Limiters Full Text
982 results on '"Jakubowiak, Andrzej"'

1. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Author

Skerget, Sheri, Penaherrera, Daniel, Chari, Ajai, Jagannath, Sundar, Siegel, David, Vij, Ravi, Orloff, Gregory, Jakubowiak, Andrzej, Niesvizky, Ruben, Liles, Darla, Berdeja, Jesus, Levy, Moshe, Wolf, Jeffrey, Usmani, Saad, Christofferson, Austin, Nasser, Sara, Aldrich, Jessica, Legendre, Christophe, Benard, Brooks, Miller, Chase, Turner, Bryce, Kurdoglu, Ahmet, Washington, Megan, Yellapantula, Venkata, Adkins, Jonathan, Cuyugan, Lori, Boateng, Martin, Helland, Adrienne, Kyman, Shari, McDonald, Jackie, Reiman, Rebecca, Stephenson, Kristi, Tassone, Erica, Blanski, Alex, Livermore, Brianne, Kirchhoff, Meghan, Rohrer, Daniel, DAgostino, Mattia, Gamella, Manuela, Collison, Kimberly, Stumph, Jennifer, Kidd, Pam, Donnelly, Andrea, Zaugg, Barbara, Toone, Maureen, McBride, Kyle, DeRome, Mary, Rogers, Jennifer, Craig, David, Liang, Winnie, Gutierrez, Norma, Jewell, Scott, Carpten, John, Anderson, Kenneth, Cho, Hearn, Auclair, Daniel, Lonial, Sagar, and Keats, Jonathan

Subjects
Humans, Multiple Myeloma, DNA Copy Number Variations, Gene Expression Regulation, Neoplastic, Exome Sequencing, Gene Expression Profiling, Female, Male, Whole Genome Sequencing, Longitudinal Studies, Disease Progression, Middle Aged
Abstract

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Multiple Myeloma Research Foundations Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile study ( NCT01454297 ) is a longitudinal, observational clinical study of newly diagnosed patients with multiple myeloma (n = 1,143) where tumor samples are characterized using whole-genome sequencing, whole-exome sequencing and RNA sequencing at diagnosis and progression, and clinical data are collected every 3 months. Analyses of the baseline cohort identified genes that are the target of recurrent gain-of-function and loss-of-function events. Consensus clustering identified 8 and 12 unique copy number and expression subtypes of myeloma, respectively, identifying high-risk genetic subtypes and elucidating many of the molecular underpinnings of these unique biological groups. Analysis of serial samples showed that 25.5% of patients transition to a high-risk expression subtype at progression. We observed robust expression of immunotherapy targets in this subtype, suggesting a potential therapeutic option.

Published
2024

2. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.

Author

Chari, Ajai, Kaufman, Jonathan, Laubach, Jacob, Sborov, Douglas, Reeves, Brandi, Rodriguez, Cesar, Silbermann, Rebecca, Costa, Luciano, Anderson, Larry, Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Holstein, Sarah, Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya, Orlowski, Robert, Shain, Kenneth, Cowan, Andrew, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas, Voorhees, Peter, Usmani, Saad, and Richardson, Paul

Subjects
Humans, Multiple Myeloma, Aged, Female, Male, Middle Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Adult, Dexamethasone, Bortezomib, Lenalidomide
Abstract

The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]). Patients received 4 induction cycles (D-RVd/RVd), high-dose therapy/transplant, 2 consolidation cycles (D-RVd/RVd), and lenalidomide±daratumumab maintenance (≤ 2 years). Minimal residual disease-negativity (10-5) rates were higher for D-RVd versus RVd in patients ≥ 65 years (67.9% vs 17.9%), with HRCAs (54.8% vs 32.4%), and with gain/amp(1q21) (61.8% vs 28.6%). D-RVd showed a trend toward improved progression-free survival versus RVd (hazard ratio [95% confidence interval]) in patients ≥ 65 years (0.29 [0.06-1.48]), with HRCAs (0.38 [0.14-1.01]), and with gain/amp(1q21) (0.42 [0.14-1.27]). In the functional high-risk subgroup (not MRD negative at the end of consolidation), the hazard ratio was 0.82 (0.35-1.89). Among patients ≥ 65 years, grade 3/4 treatment-emergent adverse event (TEAE) rates were higher for D-RVd versus RVd (88.9% vs 77.8%), as were TEAEs leading to discontinuation of ≥ 1 treatment component (37.0% vs 25.9%). One D-RVd patient died due to an unrelated TEAE. These results support the addition of daratumumab to RVd in transplant-eligible patients with high-risk NDMM. Video Abstract.

Published
2024

3. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Author

Callander, Natalie, Silbermann, Rebecca, Kaufman, Jonathan, Godby, Kelly, Laubach, Jacob, Schmidt, Timothy, Sborov, Douglas, Medvedova, Eva, Reeves, Brandi, Dhakal, Binod, Rodriguez, Cesar, Chhabra, Saurabh, Bal, Susan, Anderson, Larry, Dholaria, Bhagirathbhai, Nathwani, Nitya, Hari, Parameswaran, Shah, Nina, Bumma, Naresh, Holstein, Sarah, Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya, Orlowski, Robert, Shain, Kenneth, Cowan, Andrew, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas, Giri, Smith, Costa, Luciano, Usmani, Saad, Richardson, Paul, Voorhees, Peter, and Chari, Ajai

Subjects
Humans, Multiple Myeloma, Antibodies, Monoclonal, Female, Male, Middle Aged, Aged, Antineoplastic Combined Chemotherapy Protocols, Chromosome Aberrations, Adult, Lenalidomide, Dexamethasone
Abstract

In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]). Among 123 D-KRd patients, 43.1%, 37.4%, and 19.5% had 0, 1, or ≥2 HRCAs. Among 120 D-RVd patients, 55.8%, 28.3%, and 10.8% had 0, 1, or ≥2 HRCAs. Rates of complete response or better (best on study) for 0, 1, or ≥2 HRCAs were 90.6%, 89.1%, and 70.8% for D-KRd, and 90.9%, 78.8%, and 61.5% for D-RVd. At median follow-up (MASTER, 31.1 months; GRIFFIN, 49.6 months for randomized patients/59.5 months for safety run-in patients), MRD-negativity rates as assessed by next-generation sequencing (10-5) were 80.0%, 86.4%, and 83.3% for 0, 1, or ≥2 HRCAs for D-KRd, and 76.1%, 55.9%, and 61.5% for D-RVd. PFS was similar between studies and superior for 0 or 1 versus ≥2 HRCAs: 36-month PFS rates for D-KRd were 89.9%, 86.2%, and 52.4%, and 96.7%, 90.5%, and 53.5% for D-RVd. These data support the use of daratumumab-containing regimens for transplant-eligible NDMM with HCRAs; however, additional strategies are needed for ultra-high-risk disease (≥2 HRCAs). Video Abstract.

Published
2024

10. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Author

Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios

Subjects
Aged, Antineoplastic Agents, Appetite, Clinical Trials as Topic, Diarrhea, Fatigue, Female, Humans, Hydrazines, Hyponatremia, Male, Middle Aged, Multiple Myeloma, Nausea, Thrombocytopenia, Triazoles
Abstract

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

Published
2020

12. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Author

Jakubowiak, Andrzej, Jasielec, Jagoda, Rosenbaum, Cara, Cole, Craig, Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor, Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd, Hycner, Tyler, Turowski, Agata, Karrison, Theodore, and Zonder, Jeffrey

Subjects
carfilzomib, dexamethasone, relapsed/refractory multiple myeloma, selinexor, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytogenetic Analysis, Dexamethasone, Drug Resistance, Neoplasm, Female, Humans, Hydrazines, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Oligopeptides, Prognosis, Recurrence, Retreatment, Treatment Outcome, Triazoles
Abstract

Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose-escalation trial of twice-weekly selinexor in combination with carfilzomib and dexamethasone (SKd) to determine maximum tolerated dose in patients with RRMM (N = 21), with an expansion cohort to assess activity in carfilzomib-refractory disease and identify a recommended phase II dose (RP2D). During dose escalation, there was one dose-limiting toxicity (cardiac failure). The RP2D of twice-weekly SKd was selinexor 60 mg, carfilzomib 20/27 mg/m2 and dexamethasone 20 mg. The most common grade 3/4 treatment-emergent adverse events included thrombocytopenia (71%), anaemia (33%), lymphopenia (33%), neutropenia (33%) and infections (24%). Rates of ≥minimal response, ≥partial response and very good partial response were 71%, 48% and 14%, respectively; similar response outcomes were observed for dual-class refractory (PI and immunomodulatory drug)/quad-exposed (carfilzomib, bortezomib, lenalidomide and pomalidomide) patients (n = 17), and patients refractory to carfilzomib in last line of therapy (n = 13). Median progression-free survival was 3·7 months, and overall survival was 22·4 months in the overall population. SKd was tolerable and re-established disease control in RRMM patients, including carfilzomib-refractory patients. Registered at ClinicalTrials.gov (NCT02199665).

Published
2019

13. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Author

Sklavenitis-Pistofidis, Romanos, Aranha, Michelle P., Redd, Robert A., Baginska, Joanna, Haradhvala, Nicholas J., Hallisey, Margaret, Dutta, Ankit K., Savell, Alexandra, Varmeh, Shohreh, Heilpern-Mallory, Daniel, Ujwary, Sylvia, Zavidij, Oksana, Aguet, Francois, Su, Nang K., Lightbody, Elizabeth D., Bustoros, Mark, Tahri, Sabrin, Mouhieddine, Tarek H., Wu, Ting, Flechon, Lea, Anand, Shankara, Rosenblatt, Jacalyn M., Zonder, Jeffrey, Vredenburgh, James J., Boruchov, Adam, Bhutani, Manisha, Usmani, Saad Z., Matous, Jeffrey, Yee, Andrew J., Jakubowiak, Andrzej, Laubach, Jacob, Manier, Salomon, Nadeem, Omar, Richardson, Paul, Badros, Ashraf Z., Mateos, Maria-Victoria, Trippa, Lorenzo, Getz, Gad, and Ghobrial, Irene M.

Published
2022
Full Text
View/download PDF

14. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Author

San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, and Bahlis, Nizar J.

Published
2022
Full Text
View/download PDF

15. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Author

Vogl, Dan T, Dingli, David, Cornell, Robert Frank, Huff, Carol Ann, Jagannath, Sundar, Bhutani, Divaya, Zonder, Jeffrey, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Cole, Craig, Vij, Ravi, Jakubowiak, Andrzej, Abonour, Rafat, Schiller, Gary, Parker, Terri L, Costa, Luciano J, Kaminetzky, David, Hoffman, James E, Yee, Andrew J, Chari, Ajai, Siegel, David, Fonseca, Rafael, Van Wier, Scott, Ahmann, Gregory, Lopez, Ilsel, Kauffman, Michael, Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla D, Choe-Juliak, Cassandra, and Stewart, A Keith

Subjects
Hematology, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Active Transport, Cell Nucleus, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Dose-Response Relationship, Drug, Female, Humans, Hydrazines, Karyopherins, Male, Middle Aged, Multiple Myeloma, Progression-Free Survival, Receptors, Cytoplasmic and Nuclear, Triazoles, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.

Published
2018

17. Optimization of Older Adults by a Geriatric Assessment-Guided Multidisciplinary Clinic Prior to CAR T-Cell Therapy

Author

Yates, Samuel J., primary, Cursio, John F., additional, Artz, Andrew S, additional, Kordas, Keriann, additional, Bishop, Michael R., additional, Derman, Benjamin A., additional, Kosuri, Satyajit, additional, Riedell, Peter A, additional, Kline, Justin, additional, Jakubowiak, Andrzej, additional, Mortel, Mylove, additional, Johnson, Shalitha, additional, and Nawas, Mariam T, additional

Published
2024
Full Text
View/download PDF

18. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone

Author

Kubicki, Tadeusz, primary, Jamroziak, Krzysztof, additional, Robak, Paweł, additional, Czyż, Jarosław, additional, Tyczyńska, Agata, additional, Druzd-Sitek, Agnieszka, additional, Giannopoulos, Krzysztof, additional, Wróbel, Tomasz, additional, Nowicki, Adam, additional, Szczepaniak, Tomasz, additional, Łojko-Dankowska, Anna, additional, Matuszak, Magdalena, additional, Gil, Lidia, additional, Puła, Bartosz, additional, Szukalski, Łukasz, additional, Końska, Agnieszka, additional, Zaucha, Jan M., additional, Walewski, Jan, additional, Mikulski, Damian, additional, Czabak, Olga, additional, Robak, Tadeusz, additional, Kruk-Kwapisz, Dorota, additional, Derman, Benjamin A., additional, Major, Ajay, additional, Jakubowiak, Andrzej J., additional, and Dytfeld, Dominik, additional

Published
2024
Full Text
View/download PDF

19. Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN

Author

Silbermann, Rebecca, primary, Laubach, Jacob, additional, Kaufman, Jonathan L., additional, Sborov, Douglas W., additional, Reeves, Brandi, additional, Rodriguez, Cesar, additional, Chari, Ajai, additional, Costa, Luciano J., additional, Anderson, Larry D., additional, Nathwani, Nitya, additional, Shah, Nina, additional, Bumma, Naresh, additional, Holstein, Sarah A., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Orlowski, Robert Z., additional, Shain, Kenneth H., additional, Cowan, Andrew J., additional, Gries, Katharine S., additional, Pei, Huiling, additional, Cortoos, Annelore, additional, Patel, Sharmila, additional, Lin, Thomas S., additional, Voorhees, Peter M., additional, Usmani, Saad Z., additional, and Richardson, Paul G., additional

Published
2024
Full Text
View/download PDF

22. Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.

Author

Padmaraju, Kashyap, Kelly, Kaitlin, Jakubowiak, Andrzej J, and Derman, Benjamin A

Subjects
MULTIPLE myeloma, PATIENT safety, QUALITATIVE research, COST effectiveness, MEDICAL quality control, ANTINEOPLASTIC agents, SUBCUTANEOUS infusions, AMYLOIDOSIS, TREATMENT duration, MONOCLONAL antibodies, PRE-tests & post-tests, PREANESTHETIC medication, QUALITY assurance
Abstract

Background Daratumumab-hyaluronidase-fihj (Dara-SQ) is frequently used in the treatment of plasma cell disorders and is associated with improved outcomes. Dara-SQ was shown to be non-inferior to intravenous daratumumab (Dara-IV) in efficacy, safety, and associated with fewer administration-related reactions (ARRs). Despite the lower ARR risk with Dara-SQ, package labeling still recommends indefinite premedication. In this study, we investigated the safety of premedication discontinuation after one cycle of Dara-SQ. Materials and Methods This pre-post interventional quality improvement study included all patients aged 18 years and older diagnosed with multiple myeloma or light chain (AL) amyloidosis who received at least one dose of Dara-SQ. Patients in Arm 1 received Dara-SQ per package labeling, while patients in Arm 2 had premedication omitted (excluding dexamethasone) after cycle 1. The primary endpoint was the incidence of ARR after cycle 1. Overall ARR rate and therapy time saved were also evaluated. Results A total of 102 patients (63 in Arm 1 and 39 in Arm 2) were included. There were zero reactions in either arm after cycle 1 across 1479 Dara-SQ doses administered over a 30-month period with or without premedication omission. The overall ARR rate was 2.9% (3/102), which all occurred prior to premedication omission. Therapy timed saved from premedication omission was 194 hours in a 6-month period, equating to approximately $140 000 USD. Conclusion ARRs to Dara-SQ were rare, mild, and occurred during cycle 1 prior to premedication omission. Omission of noncorticosteroid premedication is safe, feasible, and carries substantial time and cost savings for patients and infusion centers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Author

Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya, Holstein, Sarah A., Anderson, Jr, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Richardson, Paul G., and Voorhees, Peter

Published
2022
Full Text
View/download PDF

24. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Author

Jasielec, Jagoda K., Kubicki, Tadeusz, Raje, Noopur, Vij, Ravi, Reece, Donna, Berdeja, Jesus, Derman, Benjamin A., Rosenbaum, Cara A., Richardson, Paul, Gurbuxani, Sandeep, Major, Sarah, Wolfe, Brittany, Stefka, Andrew T., Stephens, Leonor, Tinari, Kathryn M., Hycner, Tyler, Rojek, Alexandra E., Dytfeld, Dominik, Griffith, Kent A., Zimmerman, Todd M., and Jakubowiak, Andrzej J.

Published
2020
Full Text
View/download PDF

25. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Author

Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Jr, Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., and Richardson, Paul G.

Published
2020
Full Text
View/download PDF

26. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma

Author

Lin, Yi, primary, Usmani, Saad Z., additional, Berdeja, Jesús G, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer E., additional, Cohen, Adam D., additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander M., additional, Munshi, Nikhil C., additional, O'Donnell, Elizabeth, additional, de Oca, Rocio Montes, additional, Yeh, Tzu-min, additional, Banerjee, Arnob, additional, Madduri, Deepu, additional, Zhao, Hao, additional, del Corral, Christopher, additional, Koneru, Mythili, additional, Jackson, Carolyn C, additional, Geng, Dong, additional, Martin, Thomas, additional, Jagannath, Sundar, additional, and Wang, Feng, additional

Published
2024
Full Text
View/download PDF

27. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Author

Cohen, Adam D., Parekh, Samir, Santomasso, Bianca D., Gállego Pérez-Larraya, Jaime, van de Donk, Niels W. C. J., Arnulf, Bertrand, Mateos, Maria-Victoria, Lendvai, Nikoletta, Jackson, Carolyn C., De Braganca, Kevin C., Schecter, Jordan M., Marquez, Loreta, Lee, Erin, Cornax, Ingrid, Zudaire, Enrique, Li, Claire, Olyslager, Yunsi, Madduri, Deepu, Varsos, Helen, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jakubowiak, Andrzej, Einsele, Hermann, and Jagannath, Sundar

Published
2022
Full Text
View/download PDF

28. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Author

Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, and Colby, Kathryn

Published
2020
Full Text
View/download PDF

29. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Author

Knop, Stefan, Mateos, Maria-Victoria, Dimopoulos, Meletios A., Suzuki, Kenshi, Jakubowiak, Andrzej, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Losava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Wang, Jianping, Wroblewski, Susan, Kudva, Anupa, Gries, Katharine S., Fastenau, John, San-Miguel, Jesus, and Cavo, Michele

Published
2021
Full Text
View/download PDF

30. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults

Author

Derman, Benjamin A., Kordas, Keriann, Ridgeway, Jean, Chow, Selina, Dale, William, Lee, Sang Mee, Aguada, Elingel, Jakubowiak, Andrzej J., Jasielec, Jagoda, Kline, Justin, Kosuri, Satyajit, Larson, Richard A., Liu, Hongtao, Mortel, Mylove, Odenike, Olatoyosi, Pisano, Jennifer, Riedell, Peter, Stock, Wendy, Bishop, Michael R., and Artz, Andrew S.

Published
2019
Full Text
View/download PDF

32. Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Author

Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, and Colby, Kathryn

Published
2020
Full Text
View/download PDF

33. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Author

Lonial, Sagar, Nooka, Ajay K., Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Potter, Heather A., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Degli Esposti, Simona, Byrne, Julie, Opalinska, Joanna, Baron, January, Piontek, Trisha, Gupta, Ira, Dana, Reza, Farooq, Asim V., Colby, Kathryn, and Jakubowiak, Andrzej

Published
2021
Full Text
View/download PDF

36. P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY

Author

Mateos, Maria-Victoria, primary, Weisel, Katja, additional, Martin, Tom, additional, Berdeja, Jesus, additional, Jakubowiak, Andrzej, additional, Stewart, Keith, additional, Jagannath, Sundar, additional, Lin, Yi, additional, Diels, Joris, additional, Ghilotti, Francesca, additional, Thilakarathne, Pushpike, additional, Perualila, Nolen, additional, Cabrieto, Jedelyn, additional, Erler-Yates, Nichola, additional, Jackson, Carolyn C, additional, Schecter, Jordan, additional, Strulev, Vadim, additional, Haddad, Imene, additional, Costa Filho, Octavio, additional, Pacaud, Lida, additional, Einsele, Hermann, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

37. S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Munshi, Nikhil, primary, Martin, Tom, additional, Usmani, Saad Z, additional, Berdeja, Jesus, additional, Jakubowiak, Andrzej, additional, Agha, Mounzer, additional, Cohen, Adam D, additional, Deol, Abhinav, additional, Htut, Myo, additional, Lesokhin, Alexander, additional, Lin, Yi, additional, O’donnell, Elizabeth, additional, Jackson, Carolyn C, additional, Yeh, Tzu-Min, additional, Banerjee, Arnob, additional, Zudaire, Enrique, additional, Madduri, Deepu, additional, Delcorral, Christopher, additional, Pacaud, Lida, additional, and Jagannath, Sundar, additional

Published
2023
Full Text
View/download PDF

39. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Author

Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, Labotka, Richard, Palumbo, Antonio, and Anderson, Kenneth C.

Published
2020
Full Text
View/download PDF

40. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Author

Dytfeld, Dominik, primary, Radocha, Jakub, additional, Hajek, Roman, additional, Cengiz-Seval, Guldane, additional, Berkac, Meral, additional, Coriu, Daniel, additional, Derman, Benjamin, additional, Jakubowiak, Andrzej, additional, Peceliunas, Valdas, additional, Mikkala, Gabor, additional, Bołkun, Łukasz, additional, Hawrylecka, Dorota, additional, Grosicki, Sebastian, additional, Tyczyńska, Agata, additional, Zaucha, Jan Maciej, additional, Knopińska, Wanda, additional, Semeńczuk, Grażyna, additional, Morawska, Marta, additional, Giannopoulos, Krzysztof, additional, Puła, Anna, additional, Rymko, Marcin, additional, Charliński, Grzegorz, additional, Szeremet, Agnieszka, additional, Kalicińska, Elżbieta, additional, Usnarska, Lidia, additional, Wróbel, Tomasz, additional, Jamroziak, Krzysztof, additional, Druzd-Sitek, Agnieszka, additional, Romejko Jarosińska, Joanna, additional, Sawicki, Waldemar, additional, Waszczuk-Gajda, Anna, additional, Juda, Adrian, additional, Hus, Marek, additional, and Gil, Lidia, additional

Published
2023
Full Text
View/download PDF

41. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Author

Avet-Loiseau, Hervé, Fonseca, Rafael, Siegel, David, Dimopoulos, Meletios A., Špička, Ivan, Masszi, Tamás, Hájek, Roman, Rosiñol, Laura, Goranova-Marinova, Vesselina, Mihaylov, Georgi, Maisnar, Vladimír, Mateos, Maria-Victoria, Wang, Michael, Niesvizky, Ruben, Oriol, Albert, Jakubowiak, Andrzej, Minarik, Jiri, Palumbo, Antonio, Bensinger, William, Kukreti, Vishal, Ben-Yehuda, Dina, Stewart, A.Keith, Obreja, Mihaela, and Moreau, Philippe

Published
2016
Full Text
View/download PDF

42. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Author

Jakubowiak, Andrzej, Offidani, Massimo, Pégourie, Brigitte, De La Rubia, Javier, Garderet, Laurent, Laribi, Kamel, Bosi, Alberto, Marasca, Roberto, Laubach, Jacob, Mohrbacher, Ann, Carella, Angelo Michele, Singhal, Anil K., Tsao, L.Claire, Lynch, Mark, Bleickardt, Eric, Jou, Ying-Ming, Robbins, Michael, and Palumbo, Antonio

Published
2016
Full Text
View/download PDF

47. Outcomes of Older Adults Optimized By Geriatric Assessment-Guided Multidisciplinary Clinic Prior to CAR-T Therapy

Author

Yates, Samuel, primary, Artz, Andrew S., additional, Kordas, Keriann, additional, Bishop, Michael R., additional, Derman, Benjamin A., additional, Kosuri, Satyajit, additional, Riedell, Peter A., additional, Kline, Justin P., additional, Jakubowiak, Andrzej, additional, Mortel, Mylove, additional, Sheppard, Melissa, additional, Small, Alexis, additional, Johnson, Shalitha, additional, and Nawas, Mariam, additional

Published
2023
Full Text
View/download PDF

48. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, primary, Jacobus, Susanna J, additional, Richardson, Paul G., additional, Zonder, Jeffrey, additional, Voorhees, Peter M., additional, Kaufman, Jonathan L., additional, Yee, Andrew J, additional, Scott, Emma C, additional, Torka, Pallawi, additional, Libby, Edward N., additional, Reeves, Brandi, additional, Wang, Michael L., additional, Anderson, Larry D., additional, Milner, Carter, additional, Gasparetto, Cristina, additional, Agha, Mounzer, additional, Khan, Dr. Abdullah, additional, Hurd, David D, additional, Avigan, David E., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Lonial, Sagar, additional, Raje, Noopur S, additional, Medvedova, Eva, additional, McCarthy, Dr. Philip L., additional, Orlowski, Robert Z., additional, Nadeem, Omar, additional, Laubach, Jacob, additional, Pasquini, Marcelo, additional, Giralt, Sergio, additional, Masone, Kelly, additional, Samur, Mehmet, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Weller, Edie, additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2023
Full Text
View/download PDF

50. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

Author

Mateos, Maria-Victoria, primary, Weisel, Katja, additional, Martin, Thomas, additional, Berdeja, Jesús G., additional, Jakubowiak, Andrzej, additional, Stewart, A. Keith, additional, Jagannath, Sundar, additional, Lin, Yi, additional, Diels, Joris, additional, Ghilotti, Francesca, additional, Thilakarathne, Pushpike, additional, Perualila, Nolen J., additional, Cabrieto, Jedelyn, additional, Haefliger, Benjamin, additional, Erler-Yates, Nichola, additional, Hague, Clare, additional, Jackson, Carolyn C., additional, Schecter, Jordan M., additional, Strulev, Vadim, additional, Nesheiwat, Tonia, additional, Pacaud, Lida, additional, Einsele, Hermann, additional, and Moreau, Philippe, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results